XTalks

OCTOBER 11, 2023

Rybelsus is Novo’s third semaglutide product on the market, a tablet form of the drug used for the treatment of type 2 diabetes. They mimic the action of GLP-1, a hormone that helps regulate blood sugar levels by enhancing insulin secretion.

Drugs 59

Drugs Insulin Hormones FDA Approval 59

XTalks

NOVEMBER 9, 2022

Glucagon-like peptide-1 (GLP-1) receptor agonists are a newer class of diabetes drugs that have the potential to double as weight loss drugs, widening their lucrative market potentials. Novo’s obesity version of semaglutide (at a higher dose) is marketed as Wegovy and was approved in 2021. billion in 2021 to $61.6

Insulin 98

Insulin Hormones FDA Approval Sales 98

XTalks

AUGUST 2, 2023

Join us as we present an in-depth analysis of each company’s revenue, net income, R&D investments, core therapeutic areas, market presence and strategic collaborations. is a global pharmaceutical company, working across both developed and emerging markets. The FDA approved the drug over a decade ago in September 2009.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

FEBRUARY 2, 2023

Amgen’s Amjevita, the first biosimilar version of AbbVie’s blockbuster arthritis injection Humira (adalimumab), has finally hit the market this week after fetching US Food and Drug Administration (FDA) approval back in 2016. Alvotech’s biosimilar is pending FDA approval. Amjevita Launch: Cost Savings, But for Whom?

Marketing 52

Marketing FDA Approval Branding Drugs 52

XTalks

APRIL 29, 2022

These bind to their respective receptors to increase glucose metabolism by increasing insulin secretion. The promising trial results could pose a threat to Danish drugmaker Novo Nordisk’s GLP-1 agonist drug Wegovy (semaglutide), which has dominated the obesity drug market since its launch in 2021. billion in 2020 to $5.42 percent.

Trials 98

Trials Drugs FDA Approval Clinical Trials 98

XTalks

SEPTEMBER 17, 2020

Acromegaly Surrogate Endpoint: Serum growth hormone and serum insulin-like growth factor 1 (IGF-1) are acceptable surrogate endpoints for acromegaly clinical trials involving somatostatin analogs such as octreotide, lanreotide and pasireotide. Nizoral is prescribed off-label, while the others are FDA approved.

Trials 98

Trials Gene Hormones Clinical Trials 98

XTalks

JUNE 12, 2023

Other approvals included the Intellis rechargeable neurostimulator for treating chronic pain associated with diabetic peripheral neuropathy (DPN). Medtronic’s Hugo Robotic-Assisted Surgery system , released in a limited market in June 2021, has been receiving positive reviews for its performance in various surgeries.

FDA Approval 98

FDA Approval Production Sales In-Vitro 98

XTalks

MAY 20, 2022

While the drug is also being investigated for weight loss, having shown to reduce body weight by an average of 20 percent in recent results from an ongoing study, its recent approval is only for diabetes treatment. Life science industry data analytics company Evaluate Vantage predicts that Mounjaro could bring in $4.9

Insulin 52

Insulin Life Science Drugs Sales 52

XTalks

FEBRUARY 14, 2024

On the other hand, Republican senators largely defended the CEOs and the free market. Currently, in the US, three PBMs control 80 percent of the market. Some Senators were skeptical and wondered why there would be such a complex system that no one understands it. The companies are often integrated with pharmacies and insurers.

Drugs 52

Drugs Insulin Pharmacy Development 52